MXPA98007433A - Medications to treat the abuse of substances - Google Patents

Abstract

The invention provides a method for the treatment of substance abuse which comprises administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient consisting of the

Description

MEDICATIONS TO TREAT SUBSTANCE ABUSE Field of Invention This invention provides a method for using 2-methyl-4- (4-methyl-1-piperazinyl) -10H-thieno (2,3-b) (1,5) benzodiazepine, (hereinafter referred to as " olanzapine "), for the treatment of dependence on a controlled substance. The present method provides a method to help the patient who wishes to stop the ingestion of the drug, decrease the adverse symptoms upon withdrawal of the drug and minimize a relapse in the abuse of the drug.

Background of the invention.

As far as history records, each society has used "drugs that alter mood, thought and feeling." In addition, pharmacological advances have sometimes paralleled the dependence of unfortunate as well as physical behavior on agents initially consumed for therapeutic purposes. Therefore, the mitigation and eventual abandonment of dependency and REF .: 28167 Undesirable physical and psychological tolerance of a substance has been a challenge throughout history. Although there are some treatments available for such abandonment of substances of addiction and / or mind altering, there is a great need for safer and more effective treatments.

It would be particularly desirable to provide an effective treatment that could minimize the hospitalization or institutionalization of a patient. The treatment must be non-addictive and provide a favorable profile of lateral effect. It is particularly desirable to provide a method that can assist the patient who wishes to stop the ingestion of the substance and facilitate the effects of withdrawal when the patient stops ingesting the undesirable substance. It is especially desirable if the method minimizes instances of relapse in the abuse of the substance. The applicants believe that olanzapine could meet these needs.

Description of the invention.

It is known that olanzapine can provide antipsychotic activity. Olanzapine is a known compound and is described in U.S. Pat. No. 5,229,382 as useful for the treatment of schizophrenia, disorders of ezquizofrénica form, acute mania, moderate states of anxiety and psychosis. The U.S. patent No. 5,229,382 is incorporated herein by reference in its entirety. Surprisingly, and in accordance with this invention, applicants have discovered that olanzapine may be useful for the treatment of substance abuse and the abandonment of such addictive substances physically and / or psychologically.

The presently claimed invention provides a method for the treatment of a condition that is a response produced by the cessation and abandonment of the abuse of a substance that is physically and / or psychologically addictive, comprising the administration of an effective amount of olanzapine or a pharmaceutically salt acceptable to a patient in need of such treatment.

This invention further provides a method for the treatment of abuse of a substance, comprising administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient in need thereof.

This invention provides a method for the treatment of the dependence of a substance that alters the mind, thought or mood, which comprises the administration of an effective amount of olanzapine or a pharmaceutically acceptable salt thereof, to a patient who needs or desires said treatment.

This invention provides a method for aiding the patient who wishes to stop the ingestion of a substance that alters the mind, thought or mood. In addition, this invention provides a method for facilitating the adverse effects of abandonment when the patient stops ingesting the undesirable substance.

Finally, this invention provides a method for minimizing the cases of relapse in the abuse of the substance.

Such substances include, but are not limited to, opioids, hypnotic and anxiolytic drugs, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine, and benzodiazepines. Such substances also include alcohol.

Finally, the present invention provides a method for the treatment of alcohol withdrawal syndrome, comprising the administration of an effective amount, of olanzapine or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment.

The ol anzapine is from the formula or an acid addition salt thereof It is especially preferred that olanzapine is the olanzapine polymorph of Form II, which has a typical X-ray energy diffraction pattern, as represented by the following interplanar spaces: d 10.2689 8.577 7.4721 7.125 6.1549 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3. 9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007 A typical example of an X-ray diffraction pattern for Form II is as follows, where d represents the interplanar spacing and I / I-L represents the relative typical intensities: .2689 100.00 8 .577 7.96 7. , 4721 1.41 7,125 6.50 6. .1459 3.12 6 .071 5.12 . 4849 0.52 . 2181 6.86 . 1251 2.47 4. 9874 7.41 4. 7665 4.03 4. 7158 6.80 4. 4787 14.72 4. 3307 1.48 4. 2294 23.19 4,141 11.28 3. 9873 9.01 3. 12? 6 14.04 3. 5645 2.27 3. 5366 4.85 3. 3828 3.47 3. 2516 1.25 3,134 0.81 3. 0848 0.45- 3, .0638 1.34 3. .0111 3 .51 2, .8739 0 .79 2., 8102 1 .47 2. .7217 0, .20 2. .6432 1. .26 2. .6007 0. .77 The X-ray diffraction patterns set forth herein were obtained using a Siemens D5000 X-ray energy diffractometer having a wavelength of Ka radiation source of wavelength, 1 = 1. 541Á.

It is further preferred that the olanzapine polymorph of Form II, will be administered as the olanzapine polymorph of substantially pure Form II.

As used herein, "substantially pure" refers to Form II associated with less than about 5% of Form I, preferably less than about 2% of Form I, and more preferably less than about 1% of Form I. the Form I. In addition, Form II "substantially pure" will contain less than about 0.5% of related substances, wherein "related substances" refers to undesirable chemical impurities or residual solvent or water. In particular, Form II "substantially pure" must contain less than about 0.05% acetonitrile content, more preferably, less than about 0.005% acetonitrile content. Additionally, it is preferred that Form II contains less than 0.5% associated water.

The polymorph obtainable by the processes taught in the patent v382 will be designated as Form I, and has a typical X-ray energy diffraction pattern substantially as follows, obtained using a Siemens D5000 X-ray energy difractometer, where d represents the interplanar spacing: 9. 9463 8.5579 8.2445 6.8862 6. 3787 6.2439 5.5895 5.3055 4.9815 4.8333 4.7255 4.6286 4. 533 4.4624 4.2915 4.2346 4.0855 3.8254 3.7489 3.6983 3.5817 3.5064 3.3392 3.2806 3.2138 3.1118 3.0507 2. 948 2.8172 2. 7589 2.6597 2.6336 2.5956 A typical example of an X-ray diffraction pattern for Form I is as follows, where d represents the interplanar spacing and I / Il represents the relative typical intensities: 9. 9463 100.00 8., 5579 15.18 8. 2445 1.96 6. 8862 14.73 6. 3787 4.25 6., 2439 5.21 5., 5895 1.10 5. .3055 0.95 4. .9815 6.14 4, .8333 68.37 4, .7255 21.88 4 .6286 3.82 4 .533 17..83 4. 4624 5.02 4 .2915 9.19 4 .2346 18.88 4 .0855 17.29 3 .8254 6.49 3 .7489 10.64 3 .6983 14.65 3 .5817 3.04 3. .5064 9.23 3. .3392 4.67 3. .2806 1.9 6 3. 2138 2 .52 3. 1118 4.81 3. 0507 1.96 2 .948 2.40 2. 8172 2.89 2. 7589 2.27 2. 6597 1.86 2. 6336 1.10 2. 5956 1.73 Lightning energy diffraction patterns X described here, were obtained with a copper Ka of wavelength 1 = 1.541Á. The spacings interplanar in the column marked "d" are in Angstroms. The relative typical intensities are in the column marked "I / Ix".

As used herein, the term "substance abuse" should refer to the undesirable physical and / or psychological dependence of a medication. It is more preferred that the term refers to the dependence of a substance selected from the group consisting of opioids, anxiolytic and hypnotic drugs, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine and benzodiazepines. Additional compounds that produce a physical and / or psychological dependence are also contemplated. It is also preferred that the term refers to alcohol dependence. It is a preferred additional modality that the term refers to nicotine dependence.

As used herein, the term "assisting a patient who wishes to stop the abuse" means that the disturbing effect of the thought of the physically or psychologically addictive substance is minimized to allow the patient provide a more rational thinking. Such rational thinking can be measured using scales or standard tools that are known to the artisan.

The term "mind-altering substance, thought or mood" or "physically or psychologically addictive" must refer to a substance that alters the thought process. For the purposes of this invention, said substance additionally produces an undesirable physical and / or psychological dependency or tolerance. Such substances should include, but are not limited in any way to a compound selected from the group consisting of opioids, anxiolytic or hypnotic drugs, cocaine, psychedelic agents, marijuana, amphetanes, hallucinogens, phencyclidine and benzodiazepines. Said substances may include alcohol. Additionally, said substances may include nicotine.

The term "adverse effects of abandonment" must refer to the adverse condition resulting from the cessation or abandonment of substance abuse or abandonment. of a substance that alters the mind, mood or thought, where the adverse effects of abandonment are not otherwise attributable to another condition.

As used herein, the term "mammal" * should refer to the Mammalia class or higher vertebrates. The term "mammal" includes, but is not limited to, a human. The term "treatment" as used herein, includes prophylaxis in a patient susceptible to the condition named or to the decrease or elimination of the condition once it has been established.

As used herein, the term "substance abuse" refers to a condition wherein the patient suffers from physical consequences attributable to the ingestion of a substance and is unable or unwilling to stop the consumption of said substance and treatment, to facilitate the abandonment of the desired substance.

As used herein, the term "alcohol abuse" refers to a condition wherein the Patient suffers from the physical consequences attributable to the ingestion of alcohol, and is unable or unwilling to cease such consumption and treatment of alcohol to facilitate the abandonment of the desired alcohol consumption.

As used herein, the term "alcoholism" or "physical dependence on alcohol" should refer to a condition resulting from excessive consumption of alcohol. The patient who suffers from alcoholism is identified by severe dependence or addiction and an accumulated pattern of behaviors associated with drinking. Frequent poisoning is obvious and destructive; It interferes with the individual's ability to socialize and work. Many alcoholics experience failures in their marriage, absenteeism from work that can lead to being fired. Alcoholics may seek medical treatment for their drink, may suffer physical harm associated with their drinking, and may be apprehended when driving drunk. Eventually the alcoholic can be arrested for drunkenness and / or hospitalized for delirium tremens or cirrhosis of the liver.

As it is used here, the "abandonment of alcohol" must refer to the characteristic abandonment syndrome that develops after the strong and prolonged use of alcohol ceases (or there is a reduction in). The alcohol withdrawal syndrome is summarized in The Pharmacolosical BaaiH of Therapeutics by Goodman & Gillman 563 (9th Ed. 1996, Me. Graw-Hill, New York). To clarify further, alcohol withdrawal is characterized in the DSM-IV-R Diasnostic and Statistical Manual of Mental Disorders. revised, 3a. Ed. (1994) as category 291.8. The DSM-IV-R was prepared by the Task Force on Nomenclature and Statistics of the American Psychiatric Association, and provides clear descriptions of diagnostic categories. The skilled artisan will recognize that there are alternative nomenclatures, nosologies and classification systems for pathological psychological conditions, and that these systems evolve with medical and scientific progress.

Discontinuation or a reduction in excessive alcohol consumption typically results in alcohol withdrawal syndrome. The withdrawal syndrome is the continuation of symptoms and signs that accompany the abandonment of alcohol, usually starting 12 to 48 hours after a significant decrease in alcohol intake. For example, such symptoms may include tremor, weakness, sweating, gastrointestinal symptoms, increased confusion, poor sleep, and / or severe depression. These symptoms often cause distress or difficulty in social, occupational or other important areas of functioning. The present invention is most preferably used to alleviate symptoms attributed to alcohol withdrawal, when such symptoms are not due to a general medical condition and do not count better for a mental disorder.

The present invention also alleviates the negative symptoms of the abandonment of the substance that alters the mind, thought and mood, wherein said symptoms are not due to a general medical condition and do not count better for a mental disorder.

The method of the present invention is preferably administered in conjunction with a behavioral and / or educational modification program, to ensure continued abstinence from alcohol. The method of the present invention is also highly beneficial for such programs, to alleviate the suffering experienced of alcohol withdrawal during the course of said programs. Therefore, programs can be more effective by focusing on the educational and behavioral change goals, while also reducing the incidence of the non-completion program.

The results of the pharmacological studies show that olanzapine has a cholinergic muscarinic receptor activity. The compound is active at the dopamine D-1 and D-2 receptors, as indicated by an IC 50 of less than 1 uM in 3H-SCH233390 (Billard, et al., Life Sciences 35: 1885 (1984)) and 3 H spiperone binding assays (Seeman et al, Nature 216: 717 (1976)) respectively. In addition, olanzapine is active at the 5-HT-2 and 5-HT1C receptor. The pharmacological profile of the complex of the compound, provides a drug that can be useful for the treatment of a condition resulting from the Cessation and abandonment of the use of a substance for which the patient has developed a dependency. In addition, the pharmacological profile of the compound complex provides a medicament that may be useful for modulating the average mass of the posterior brain to interfere with the mediated perpetuation of the "pleasure trajectory" of the abuse cycle. See C.K. Erickson, Alcohol & Alcoholism, 31 Sup. 1, pp 5-11 (1996).

The utility of the compound for the treatment of a condition resulting from the cessation or abandonment of the use of a substance that produces dependence, can be supported by the following studies as described.

Response to Hearing Stimuli Male Long Evans rats (Harían Sprague Dawley) were housed individually in a controlled medium during a light cycle-dark of 12 hours. The rats were given free access to food and water. All treatment groups contained 8 to 10 rats.

The rats were anesthetized with halothane and Alzet osmotic minipumps were implanted subcutaneously (Alza Corporation, Palo Alto, California). A substance producing dependence, such as an opioid, was supplied in the physiological saline solution. The pumps were filled with opioid (6mg / kg base / day) or the appropriate vehicle. Twelve days after the implantation of the pumps, the rats were anesthetized with halothane and the pumps were separated. (The study was also conducted with other dependence-producing substances such as marijuana, and so on).

The response to the auditory stimulus was observed.

The sensory motor reactions (response to the auditory stimulus (peak amplitude, Vmax) of the individual rats were recorded using the stimulus chambers of San Diego Instruments (San Diego, Calif.) The stimulation sessions consist of a period of adaptation 5 minutes at a background noise level of 70 +/- 2dBA, immediately followed by 25 presentations of auditory stimuli (120 +/- 3 dBA of noise, 50 ms of duration) presented at 8-second intervals.

Peak amplitudes of stimuli were averaged for all 25 stimulus presentations for each session. The response to the auditory stimulus is evaluated daily at 24-hour intervals on days 1-4 following the discontinuation of the substance.

In addition, the usefulness of the compound to assist the patient who wishes to stop the ingestion of an undesirable addictive substance, to diminish the symptoms of adverse abandonment, and to minimize the incidence of relapse in the abuse can be shown using the following study: Clinical Observations A double-blind, multi-center clinical trial was designed to evaluate the safety and efficacy of olanzapine. Patients were taken at random for olanzapine or placebo. The results of the study suggest that olanzapine may be useful for the treatment of withdrawal of the substance that creates addiction.

Olanzapine is effective over a wide range of doses, the current dose administered depends on the condition to be treated. For example in the treatment of human adults, doses of from about 0.25 to 50 mg, preferably from 1 to 30 mg, and more preferably from 1 to 25 mg per day can be used. A dose once a day is usually sufficient, although divided doses may be administered. For the treatment of a condition resulting from the cessation and cessation of the use of an addictive substance, a dose range from 1 to 30 mg, preferably from 1 to 20 mg per day is appropriate. For the treatment of alcohol abuse, a lower dose may be more appropriate. Similarly, for the treatment of cessation of nicotine use, a lower dose may be more appropriate.

A preferred formulation of the invention is a solid formulation comprising from about 1 to about 25 mg or from 1 to 15 mg of olanzapine as an effective amount of the active ingredient.

More preferably, the oral solid formulation is contained in packaging materials that protect the formulation from moisture and light. For example, suitable packaging materials include amber colored high density polyethylene bottles, amber glass bottles, and other containers made of a material that inhibits the passage of light. More preferably, the package will include a desiccant package. The container can be sealed with a blister of aluminum laminate to provide the desired protection and preserve the stability of the product.

Olanzapine will normally be administered orally or by injection and for this purpose, it is usually employed in the form of a pharmaceutical composition.

Accordingly, pharmaceutical compositions comprising olanzapine as an active ingredient associated with a pharmaceutically acceptable carrier can be prepared. In making the compositions of the invention, the conventional techniques for the preparation of pharmaceutical compositions. For example, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or housed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it can be a solid, semi-solid or liquid material, which acts as a vehicle, excipient or medium for the active ingredient. The active ingredient can be adsorbed on a granular solid container for example in a sack. Examples of suitable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl-hydroxy-benzoate, talc, stearate of magnesium or mineral oil. The compositions of the invention may if desired be formulated so as to provide a rapid, sustained or delayed release of the active ingredient, after administration to the patient.

Depending on the method of administration, the compositions for the treatment of Central nervous system conditions can be formulated as tablets, capsules, injectable solutions for parenteral use, gel or suspension for transdermal delivery, suspensions or elixirs for oral use or suppositories. Preferably the compositions are formulated in unit dose form, each dose contains 0.25 to 25 mg, more usually 1 to 25 mg of the active ingredient.

The materials for the present invention can be purchased or prepared by a variety of methods well known to those of ordinary skill in the art. Olanzapine can be prepared as described by Chakrabarti in U.S. Pat. No. 5,229,382 ('382), incorporated herein by reference in its entirety. In addition, the following preparations illustrate a method for the preparation of the especially preferred Form II olanzapine polymorph.

Compound characterization methods include, for example, X-ray energy pattern analysis, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), Titration analysis for water, and HL-NMR analysis for solvent content.

The following examples are provided for purposes of illustration and should not be construed as limiting the scope of the claimed invention.

Preparation 1 Technical Grade Olanzapine Intermediary 1 In an appropriate three-necked flask, the following was added: Dimethyl sulfoxide (analytical) 6 volumes Intermediate 1: 75 g N-methylpiperazine (reactive) 6 equivalents Intermediate 1 can be prepared using methods known to the skilled artisan. For example, the preparation of Intermediate 1 is taught in the patent? 382.

A bubbling line of sub-surface nitrogen was added to remove the ammonia formed during the reaction. The reaction was heated to 120 C and maintained at that temperature throughout the duration of the reaction. The reactions were followed by HPLC until 5% of intermediate 1 was left unreacted. After the reaction was complete, the mixture was allowed to cool slowly to 20 C (about 2 hours). The reaction mixture was then transferred to a suitable 3-necked round bottom flask and a water bath. To this solution with stirring, 10 volumes of reagent grade methanol were added and the reaction was stirred at 20 C for 30 minutes. Three volumes of water were added slowly for about 30 minutes. The reaction suspension was cooled to zero to 5 C and stirred for 30 minutes. The product was filtered and the wet cake was washed with ice-cold methanol. The wet cake was dried in vacuo a 45 C during the night. The product was identified as olanzapine technique.

Yield: 76.7%; Power: 98.1% Preparation 2 Form II olanzapine polymorph A 270 g sample of 2-methyl-4- (4-methyl-1-piperazinyl) -lOH-thieno (2,3-b) (1,5) benzodiazepine was suspended in anhydrous ethyl acetate (2.7 L). The mixture was heated to 76 C and maintained at 76 C for 30 minutes. The mixture was allowed to cool to 25 C. The resulting product was isolated using vacuum filtration. The product was identified as Form II using X-ray energy analysis. Yield: 197 g.

The process described above, for the preparation of Form II, provides a pharmaceutically elegant product having a potency > . to 97%, total substances released < at 0.5% and an isolated yield of > 73%.

A portion of hydroxypropyl cellulose was dissolved in purified water to form a solution for granulation. The remaining hydroxypropyl cellulose (total 4.0% w / w final tablet weight), which has an extra fine grade, was combined with olanzapine (1.18% w / w), lactose (79.32% w / w) and a portion of crospovidone (5% w / w) in a high-effort granulator. All the ingredients were screened for safety, before addition and dry mixing in the granulator. This mixture was then granulated with the hydroxypropyl cellulose solution in the high stress granulator. The granulation was classified by wet dimensions using conventional methods. The wet granulation was then dried in a fluidized bed dryer and sorted by dimensions. The material was then added to a dump tank mixer.

The resulting powders consisted of microcrystalline (granular) cellulose (10% w / w), magnesium stearate (0.5% w / w) and the rest of the crospovidone was added to the dimensioned granulation. The mixture was mixed and compressed with the appropriate tooling in the tablet compression equipment.

Bottom coating: The hydroxypropyl methylcellulose (10% w / w) was mixed with purified water to form a solution. The core tablets were divided into approximately equal sections and spray coated with the hydroxypropyl methyl cellulose solution. The operation was carried out in a perforated coating vessel Coating of the Core Tablets: The White Color Mixture (hydroxypropyl methylcellulose, polyethylene glycol, polysorbate 80 and titanium dioxide) was mixed with purified water to form the coating suspension. The undercoated tablets were divided into roughly equal sections and spray coated with the coating suspension arrib «to described. The operation was carried out in a perforated coating vessel.

The coated tablets were lightly powdered with carnauba wax and printed with proper identification.

It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.

Having described the invention as above, the content r is claimed as property in the following.

Claims (49)

Claims

1. The use of olanzapine or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of abuse of a substance in a mammal.

2. The use according to claim 1, characterized in that the abuse of a substance is physical dependence on a compound selected from the group consisting of opioids, hypnotic and ansiolí ticas drugs, cocaine, psychedelic agents, marijuana, etóiminas anf, hallucinogens, phencyclidine and benzodiazepines.

3. The use according to claim 2, wherein the compound is selected from the group consisting of hypnotic drugs and ansiolí ticas, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine, and benzodiazepines.

4. The use according to claim 2, characterized in that the physical dependence is on an opioid.

5. The use according to claim 1, characterized in that olanzapine is an olanzapine of Form II, which has a typical diffraction pattern of X-ray energy, presented as follows, where d represents the interplanar space: d 10.2689 8.577 7.4721 7.125 6.1549 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4. 3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007

6. The use according to claim 2, characterized in that olanzapine is an olanzapine of Form II, which has a diffraction pattern typical of energy of X rays, presented as follows, wherein d represents the interplanar spacing: d 10.2689 8,577 7.4721 7,125 6.1549 6,071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4,141 3.9873 3.7206 3.5645 3. 2516 3,134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007

7. The use of olanzapine or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of a condition which is a response produced by the cessation and withdrawal of the use of a physical and psychological addictive substance.

8. The use according to claim 7, characterized in that it is the response to the withdrawal syndrome of the substance.

9. The use according to claim 7, characterized in that olanzapine is the olanzapine polymorph of Form II, which has a typical X-ray energy diffraction pattern, as represented as follows, where d represents the interplanar spaces: d 10.2689 8.577 7.4721 7.125 6.1549 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3. 7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007

10. The use according to claim 7, characterized in that the effective amount is from about 1 mg to about 25 mg per day.

11. The use according to claim 9, characterized in that the effective amount is from about 1 mg to about 20 mg per day.

12. A use for treating substance abuse, characterized in that it comprises administering to a mammal in need of such treatment, an effective amount of olanzapine, or a pharmaceutically acceptable salt thereof.

13. The use of aolanzapine or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a patient who wants to stop substance abuse, wherein the substance is physically or psychologically addictive.

14 The use according to claim 13, wherein the substance abuse is physical dependence on a compound selected from the group consisting of opioids, hypnotic and anxiolytic drugs, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine, and benzodiazepines .

15. A use according to claim 14, wherein the compound is selected from the group consisting of anxiolytic and hypnotic drugs, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine, and benzodiazepines.

16. A use according to claim 15, characterized in that the physical dependence is of an opioid.

17. A use according to claim 16, characterized in that olanzapine is the olanzapine polymorph of Form II, which has a typical X-ray energy diffraction pattern, as represented by the following, where d represents the interplanar space: 10. 2689 8.577 7. 4 7 2 1 7. 12 5 6. 1459 6. 071 5. 4849 5. 2181 5. 1251 4. 9874 4. 7665 4.7158 4. 4787 4. 3307 4. 2294 4. 141 3. 9873 3. 7206 3. 5645 3. 5366 3. 3828 3. 2516 3. 134 3. 0848 3. 0638 3. 0111 2. 8739 2. 8102 2. 7217 2. 6007

18. The use of olanzapine or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a patient who wants to stop the dependence of a substance that alters the mind, thought or mood.

19. The use according to claim 18 characterized in that the substance that alters the mind, thought or mood is alcohol. ,

A use according to claim 18, characterized in that the substance that alters the mind, thought or mood is nicotine.

21. The use according to claim 18, characterized in that the substance that alters the mind, thought and mood is a compound selected from the group that It consists of opioids, hypnotic and anxiolytic drugs, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine and bepzodiazepines.

22. A use according to claim 21, characterized in that the substance that alters the mind, thought and mood is a compound selected from the group consisting of cocaine, opioids and amphetamines.

23. The use of olanzapine or a pharmaceutically acceptable salt thereof for the preparation of a medicament for facilitating the adverse effects of the relapse of a substance that alters the mind, thought and mood, which is physical and / or or psychologically addictive.

24. The use according to claim 23, characterized in that the substance is physically addictive.

25. The use according to claim 24, characterized in that the substance that alters the mind, thought and spirit is alcohol.

26. The use according to claim 24, characterized in that the substance that alters the mind, thought and mood is nicotine.

27. The use according to claim 24, characterized in that the substance that alters the mind, thought and anime is a compound selected from the group consisting of opioids, hypnotic drugs and anxiolytics, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens. , phencyclidine and benzodiazepines.

28. The use according to claim 27, characterized in that the substance that alters the mind, thought and mood is selected from the group consisting of cocaine, opioids and amphetamines.

29. The use of olanzapine or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for minimizing the frequency of relapse to the substance of abuse for a patient who is addicted to a substance that alters the mind, thought and cheer up.

30. The use according to claim 29, characterized in that the substance of abuse is a compound selected from the group consisting of opioids, hypnotic and anxiolytic drugs, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine and benzodiazepines.

31. The use according to claim 29, characterized in that the substance of abuse is alcohol.

32. The use according to claim 31, characterized in that the substance of abuse is nicotine.

33. The use according to claim 29, characterized in that the Mammy was physically addicted to a substi- tute that tera the mind, thought and encouragement for two years.

34 .. The use of olanzapine or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of alcohol abuse in a mammal.

35. The use according to claim 34, characterized in that the abuse of alcohol is physical dependence on alcohol.

36. The use according to claim 35, characterized in that the physical dependence in alcohol is alcoholism.

37. The use according to claim 34, characterized in that olanzapine is the olanzapine polymorph of Form II, which has a typical X-ray energy diffraction pattern, as represented by the following, where d represents the interplanar space: d 10. 2689 8. 577 7.4721 7.125 6.1549 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3. 0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007

38. The use according to claim 35, characterized in that olanzapine is the olanzapine polymorph of Form II, which has a typical X-ray energy diffraction pattern, as represented by the following, wherein d represents the interplanar space: 10. 2689 8.577 7.4721 7.125 6.1549 6.071 5. 2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007

39. The use of olanzapine or a pharmaceutically acceptable salt thereof for the preparation of an edicement to treat a condition that is a response produced by the cessation and cessation of alcohol abuse in a patient.

40. The use according to claim 39, characterized in that it responds to the alcohol withdrawal syndrome.

41. The use according to claim 39, characterized in that olanzapine is the olanzapine polymorph of Form II, which has a typical diffraction pattern of X-ray energy, as represented by the following, wherein d represents the interplanar space: d 10.2689 8.577 7.4721 7.125 6.1549 6. 071 5. 4849 5. 2181 5. 1251 4. 9874 4. 7665 4. 7158 4. 4787 4. 3307 4. 2294 4. 141 3. 9873 3. 7206 3. 5645 3. 5366 3. 3828 3.2516 3. 134 3. 0848 3. 0638 3. 0111 2. 8739 2. 8102 2. 7217 2. 6432 2. 6007

42. The use according to claim 39, characterized in that the effective amount is from 1 mg to 25 mg per day.

43. The use according to claim 41, characterized in that the effective amount is from 1 mg to 20 mg per day.

44. An olanzapine or a pharmaceutically acceptable salt thereof, characterized porqiie is for use in minimizing the frequency of relapse to substances of abuse.

45. An olanzapine or a pharmaceutically acceptable salt thereof, characterized in that it is for use in helping a patient who wants to stop the abuse of a substance that alters the mind, thought and mood.

46. An olanzapine or a pharmaceutically acceptable salt thereof, characterized in that it is used in the treatment of a condition that is a response produced by the cessation and cessation of alcohol abuse.

47. An olanzapine or a pharmaceutically acceptable salt thereof, characterized in that it is used in the treatment of alcohol abuse.

48. An olanzapine or a pharmaceutically acceptable salt thereof, characterized in that it is easily used in the adverse effects of substances that alter the mind, thought and mood with physical or psychological addictions.

49. An olanzapine or a pharmaceutically acceptable salt thereof, characterized in that it is used in the treatment of a condition which is a response produced by the cessation and abandonment of the use of an addictive substance physically or psychologically.